|
Match
|
Document |
Document Title |
|
|
6399078 |
Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
The present invention provides therapeutic compositions of receptor ligand-containing antagonist complexes and methods of using them to treat diseases, disorders or conditions associated with the...
|
|
|
6391339 |
Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
The invention relates to the use of a certain oligosaccharide for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment.
|
|
|
6384021 |
Heparin compositions of very low molecular weight
Compositions of heparins of very low molecular weight, with the formula I, in which, n may vary between 1 and 12; R 1 =H or SO 3 Na; R 2 =SO 3 Na or COCH 3 . Such compositions of heparin are...
|
|
|
6380173 |
Use of low-molecular-weight heparins for the prevention and treatment of trauma of the central nervous system
Trauma of the central nervous system is prevented and treated by administering an effective amount of a low molecular weight heparin.
|
|
|
6355626 |
Antithrombin agents in treatment of asthma
Methods of inhibiting calcium release and proliferation in human airway smooth muscle cells by contacting cells with an antithrombin agent are provided. These antithrombin agents are useful in the...
|
|
|
6346517 |
Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for...
|
|
|
6340675 |
Process for the production of an anticoagulant composition
A process is disclosed for the production of an anticoagulant composition which allows for the accurate analysis of blood electrolyte concentrations. Also disclosed is the anticoagulant composition...
|
|
|
6339074 |
Sulfated hyaluronic acid and esters thereof
Hyaluronic acid, hyaluronate esters and salts thereof are sulfated such that the number of sulfate groups per monomeric unit is in the range of from 0.5 to 3.5. The sulfated derivatives exhibit...
|
|
|
6331523 |
Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
The present invention relates to the use of FGF-5 polypeptides to delay, prevent or rescue retinal neurons, including photoreceptors, other retinal cells or supportive cells (e.g. Muller cells or...
|
|
|
6329351 |
Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk
Sulphaminoheparosansulphates obtainable from the Escherichia coli K5 polysaccharide by deacetilation and the subsequent sulfation with the sulphuric anhydride/trimethylamine adduct carried out at...
|
|
|
6326017 |
Methods for the localized delivery of agents to blood vessels
Methods for the localized delivery of agents to blood vessels are disclosed. The methods of the present invention provide advantages over existing methods for treating, diagnosing, or preventing,...
|
|
|
6313104 |
Organoprotective solutions
The invention relates to the use of polysulfated glycosaminoglycans having a sulfur content of at least 12.5% for producing pharmaceutical preparations for inhibiting the γ-interferon-induced...
|
|
|
6313088 |
8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
|
|
6303585 |
Cross-linked polysaccharide drug carrier
A carrier and a method for preparing it are provided for use in the delivery of therapeutic agents. A polysaccharide is reacted with an oxidizing agent to open sugar rings on the polysaccharide to...
|
|
|
6291439 |
Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
The present invention provides methods for measuring endogenous heparin in a mammal at levels that were previously undetectable. The present invention further features methods for assessing the...
|
|
|
6288043 |
Injectable hyaluronate-sulfated polysaccharide conjugates
An injectable composition is provided for promoting bone and/or cartilage growth comprising hyaluronic acid cross-linked to sulfated polysaccharide through linking groups. The linking groups are...
|
|
|
6288044 |
O-sulfated bacterial polysaccharides
Process for the preparation of O-sulfated K4, K5 and K40 polysaccharides useful for the treatment of tumoral, HIV-1 and coagulation pathologies and in cosmetic preparations, wherein the K4, K5 or...
|
|
|
6288113 |
Angiogenesis promoters
An angiogenesis promoter containing a compound of the following formula (I) ##STR1## wherein R 1 is acyl, R 2 is alkyl, R 3 and R 4 are the same or different and each is hydrogen atom or...
|
|
|
6258798 |
Method for treatment of unstable coronary artery disease by an early revascularisation together with administration of a low molecular weight heparin
The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight...
|
|
|
6258797 |
Combating infection in delivery systems
The use of taurolidine or taurultam in a method of combatting infection or sepsis in delivery systems is disclosed. In the method, taurolidine or taurultam solutions are used as a temporary seal or...
|
|
|
6255296 |
Composition and method for treating a patient susceptible to or suffering from a cardiovascular disorder or disease
A method for inhibiting the effects of cardiovascular disorders and diseases in a host susceptible to or suffering from a cardiovascular disorder or disease comprising administering to the host, a...
|
|
|
6245753 |
Amphiphilic polysaccharide derivatives
Polysaccharides, which are widely used as an anticoagulation drugs, especially heparin, are clinically administered only by intravenous or subcutaneous injection because of their strong...
|
|
|
6235725 |
Methods and compositions for the prevention of tolerance to medications
The present invention pertains to the identification of moieties and methods of using the same for preventing tolerance to bronchodilators. More specifically, the present invention pertains to the...
|
|
|
6235709 |
Inhibitor of helicobacter pylori colonization
The present invention provides a safe and effective inhibitor of Helicobacter pylori colonization in the stomach and a food containing the inhibitor. The inhibitor of the present invention...
|
|
|
6232302 |
Agents and compositions thereof for the hair treatment
Compositions containing depolymerized fucane sulphates characterized by the following parameters (percentages by weight on the dry product): Molecular weight: 5,000-30,000 dalton; Sulphur:...
|
|
|
6221855 |
Regulation of nucleic acid expression by heparan sulfate and biological equivalents thereof
The present invention relates to the use of heparan sulfate, or a biological equivalent thereof, to regulate nucleic acid expression, expression of cell receptors, and infection by hepatitis B virus.
|
|
|
6207653 |
Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
The use of heparin or heparan sulphate in combination with chitosan for the manufacture of a medicament for the prevention or treatment of infections caused by herpes virus in mammal including man;...
|
|
|
6200588 |
Blood-compatible composition and medical device using same
The present invention provides a blood-compatible composition containing an ionic complex consisting of an organic cationic compound and heparin or a derivative thereof, wherein the organic...
|
|
|
6197568 |
Method and compositions for isolation, diagnosis and treatment of polyanion-binding microorganisms
Methods and compositions for the isolation, diagnosis and treatment of microorganisms such as flaviviruses and other hemorrhagic fever viruses are based on the sulfated polyanion-dependent...
|
|
|
6194394 |
Coagulation controls for prothrombin time (PT) and activated partial thromboplastin time (APTT) assays
Coagulation control compositions suitable for use in connection with PT and/or APTT assays are disclosed along with their methods of preparation and methods of use. Preferred coagulation controls...
|
|
|
6174863 |
Carbohydrate derivatives
The invention relates to a carbohydrate derivative having formula I ##STR1## wherein R 1 is (1-4C)alkoxy; R 2 , R 3 and R 4 are independently (1-4C)alkoxy or OSO 3 - , the total number of...
|
|
|
6162797 |
Derivatives of K5 polysaccharide having high anticoagulant activity
Derivatives of the K5 polysaccharide having anticoagulant activity higher than heparin, obtained by a process including the steps of reacting: with an organic base a solution of K5 polysaccharide...
|
|
|
6150115 |
Quantitative determination method for heparan sulfate and diagnostic method using the same
The present invention relates to a quantitative determination method for heparan sulfate in body fluid specimens of various chronic diseases, in urine samples of diabetic nephropathy and for...
|
|
|
6150342 |
Heparin derivatives for treatment of angina pectoris
|
|
|
6136794 |
Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
A method for inhibiting platelet aggregation in a mammal comprising administering to the mammal a safe and therapeutically effective amount of a GPIIb/IIIa receptor antagonist or a pharmaceutically...
|
|
|
6133325 |
Bioresorbable compositions of carboxypolysaccharide polyether intermacromolecular complexes and methods for their use in reducing surgical adhesions
The present invention relates to improved methods for making and using-bioadhesive, bioresorbable, anti-adhesion compositions made of intermacromolecular complexes of carboxyl-containing...
|
|
|
6130210 |
Heparin derivatives having antimetastatic activity
Heparin derivatives are disclosed that may be used to inhibit formation of metastases. One series of heparin derivatives of the invention are N-acylated with monocarboxylic acids or dicarboxylic...
|
|
|
6127347 |
Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with...
|
|
|
6117425 |
Supplemented and unsupplemented tissue sealants, method of their production and use
This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation...
|
|
|
6103705 |
Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
The invention is also directed to pharmaceutical composition comprising a compound having anti-Xa activity, a platelet aggregation antagonist compound and a pharmaceutically acceptable carrier. The...
|
|
|
6096705 |
Inhibition of agonist-specific desensitization of β2 adrenergic receptors
The present invention relates to a method of inhibiting desensitization of a cell to the effects of a compound. The method comprises contacting the cell with an agent capable of inhibiting...
|
|
|
6096525 |
Bonding bio-active materials to expanded polytetrafluoroethylene or polyethylene terephthalate via an isocyanate-terminated spacer
A bio-active material such as heparin, urokinase or streptokinase is bonded via a hydrophilic spacer to a functionality on the surface of a hydrophobic, bio-compatible polymeric substrate to...
|
|
|
6090794 |
Inhibition of neurofibrosarcoma growth and angiogenesis
A method for treating a neurofibrosarcoma tumor comprising administration of heparin and an angiostatic steroid is disclosed. Animal models for the growth of neurally-derived tumors and for testing...
|
|
|
6083933 |
Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
Cystitis of the bladder and urinary tract, particularly interstitial cystitis, are treated using effective unit doses of chondroitin sulfate. Further, cystitis patients are screened for their...
|
|
|
6080732 |
Use of sulodexide and of the medicines containing it in the treatment of the diabetic retinopathy
The use of sulodexide, a glycosaminoglycan of natural origin extracted from mammalian intestinal mucosa, and of medicines containing it in the treatment of patients suffering from retinopathy of...
|
|
|
6077683 |
Method of synthesis of desulfated heparin and use thereof for inhibition of elastase and cathepsin
A method and medicament for the inhibition of neutrophil elastase and cathepsin G in mammals comprising administering a treatment effective amount of 2-O-desulfated heparin to a mammal in need...
|
|
|
6075013 |
Modified low molecular weight heparin that inhibits clot associated coagulation factors
The present invention provides compositions and methods for the treatment of cardiovascular diseases. More particularly, the present invention relates to modifying thrombus formation by...
|
|
|
6071510 |
Modified amino acids and compositions comprising the same for delivering active agents
The present invention provides modified amino acids for delivering active agents, and particularly biologically or chemically active agents. The preferred modified amino acids of the present...
|
|
|
6060460 |
Use of betaglycan to reduce scarring
The present invention concerns soluble betaglycan for use in promoting the healing of wounds or fibrotic disorders with reduced scarring, together with methods for same.
|
|
|
6024954 |
Compositions and methods for disinfecting contact lenses and preserving contact lens care products
Compositions for disinfecting contact lenses include a liquid medium containing a chlorite component, preferably a water soluble chlorite component, in a contact lens disinfecting amount, and a...
|